Clinical Trial: Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine i

Brief Summary: The aim of this study is to investigate the immunogenicity response in adults up to 10 years after one booster dose. Data collected from this study will allow for greater information to prescribers who administer TBE vaccine, so that they can appropriately time the administration of booster vaccinations to individuals who received different vaccination schedules and who live in tick borne encephalitis endemic regions.

Detailed Summary:
Sponsor: GlaxoSmithKline

Current Primary Outcome: Antibody responses in subjects for up to 10 years following booster vaccination. [ Time Frame: 6 to 10 years after first booster with TBE vaccination ]

Original Primary Outcome: To measure antibody responses in subjects for up to 10 years following booster vaccination. [ Time Frame: 5 years immunogenicity data ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: GlaxoSmithKline

Dates:
Date Received: March 13, 2012
Date Started: March 2012
Date Completion:
Last Updated: March 21, 2017
Last Verified: March 2017